WO1999033982A3 - Genes humains et produits d'expression genique i - Google Patents

Genes humains et produits d'expression genique i Download PDF

Info

Publication number
WO1999033982A3
WO1999033982A3 PCT/US1998/027610 US9827610W WO9933982A3 WO 1999033982 A3 WO1999033982 A3 WO 1999033982A3 US 9827610 W US9827610 W US 9827610W WO 9933982 A3 WO9933982 A3 WO 9933982A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
gene expression
expression products
human genes
polynucleotides
Prior art date
Application number
PCT/US1998/027610
Other languages
English (en)
Other versions
WO1999033982A2 (fr
Inventor
Lewis T Williams
Jaime Escobedo
Michael A Innis
Pablo Dominguez Garcia
Julie Sudduth-Klinger
Christoph Reinhard
Klaus Giese
Filippo Randazzo
Giulia C Kennedy
David Pot
Altaf Kassam
George Lamson
Radoje Drmanac
Radomir Crkvenjakov
Mark Dickson
Snezana Drmanac
Ivan Labat
Dena Leshkowitz
David Kita
Veronica Garcia
Lee William Jones
Birgit Stache-Crain
Original Assignee
Chiron Corp
Hyseq Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Hyseq Inc filed Critical Chiron Corp
Priority to JP2000526638A priority Critical patent/JP2002500010A/ja
Priority to EP98965500A priority patent/EP1190058A2/fr
Priority to AU20955/99A priority patent/AU2095599A/en
Publication of WO1999033982A2 publication Critical patent/WO1999033982A2/fr
Publication of WO1999033982A3 publication Critical patent/WO1999033982A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention porte sur de nouveaux polynucléotides humains et des variantes de ceux-ci, sur leurs polypeptides codés et les variantes de ceux-ci, sur des gènes correspondant à ces polynucléotides et sur des protéines exprimées par ces gènes. L'invention porte également sur des agents diagnostiques et thérapeutiques utilisant ces nouveaux polynucléotides humains, sur leurs gènes ou produits géniques correspondants tels que ces gènes et protéines, y compris des sondes, des produits de recombinaison antisens et des anticorps.
PCT/US1998/027610 1997-12-23 1998-12-22 Genes humains et produits d'expression genique i WO1999033982A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000526638A JP2002500010A (ja) 1997-12-23 1998-12-22 ヒト遺伝子および遺伝子発現産物ｉ
EP98965500A EP1190058A2 (fr) 1997-12-23 1998-12-25 Genes humains et produits 1 gene expression
AU20955/99A AU2095599A (en) 1997-12-23 1998-12-25 Human genes and gene expression products i

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US6875597P 1997-12-23 1997-12-23
US60/068,755 1997-12-23
US8066498P 1998-04-03 1998-04-03
US60/080,664 1998-04-03
US10523498P 1998-10-21 1998-10-21
US60/105,234 1998-10-21
US10587798P 1998-10-27 1998-10-27
US60/105,877 1998-10-27
US21747198A 1998-12-21 1998-12-21
US09/217,471 1998-12-21

Publications (2)

Publication Number Publication Date
WO1999033982A2 WO1999033982A2 (fr) 1999-07-08
WO1999033982A3 true WO1999033982A3 (fr) 1999-12-23

Family

ID=27535805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/027610 WO1999033982A2 (fr) 1997-12-23 1998-12-22 Genes humains et produits d'expression genique i

Country Status (4)

Country Link
EP (1) EP1190058A2 (fr)
JP (1) JP2002500010A (fr)
AU (1) AU2095599A (fr)
WO (1) WO1999033982A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617438B1 (en) * 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US8101349B2 (en) 1997-12-23 2012-01-24 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells and their methods of use II
EP1092024A2 (fr) 1998-06-30 2001-04-18 Millennium Pharmaceuticals, Inc. Recepteur 14273, recepteur couple a une proteine g
US6448005B1 (en) * 1998-06-30 2002-09-10 Millennium Pharmaceuticals, Inc. 14723 Receptor, a novel G-protein coupled receptor
US7534579B2 (en) 1998-06-30 2009-05-19 Millennium Pharmaceuticals, Inc. 14273 receptor, a novel G-protein coupled receptor
US6395877B1 (en) 1998-06-30 2002-05-28 Millennium Pharmaceuticals, Inc. 14273 receptor, a novel G-protein coupled receptor
EP1144636A2 (fr) * 1998-09-28 2001-10-17 Chiron Corporation GèNES HUMAINS ET LEURS PRODUITS D'EXPRESSION
CA2359701A1 (fr) * 1999-01-29 2000-08-03 Incyte Pharmaceuticals, Inc. Proteines liant des acides nucleiques
WO2000050443A2 (fr) 1999-02-26 2000-08-31 Millennium Pharmaceutcals, Inc. Proteines secretees et leurs utilisations
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
US6647341B1 (en) 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
AU4484400A (en) * 1999-04-23 2000-11-10 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
AU6181300A (en) * 1999-07-29 2001-02-19 Helix Research Institute Liver cancer-associated genes
ES2272309T3 (es) 1999-08-03 2007-05-01 Millennium Pharmaceuticals, Inc. 15571, una nueva molecula de tipo gpcr de la familia de tipo secretina y sus usos.
CN1300845A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人二酰基甘油蛋白激酶亚单位9和编码这种多肽的多核苷酸
WO2001049879A2 (fr) * 1999-12-29 2001-07-12 Aros Applied Biotechnology Aps Expression genique et etats biologiques
DE10004102A1 (de) * 2000-01-31 2002-06-20 Metagen Pharmaceuticals Gmbh Nachweis von differenzieller Genexpression
US20020102640A1 (en) * 2000-02-09 2002-08-01 Hubert Rene S. 83P5G4: a tissue specific protein highly expressed in prostate cancer
US6627423B2 (en) 2000-03-24 2003-09-30 Millennium Pharmaceuticals, Inc. 21481, a novel dehydrogenase molecule and uses therefor
US6511834B1 (en) 2000-03-24 2003-01-28 Millennium Pharmaceuticals, Inc. 32142,21481,25964,21686, novel human dehydrogenase molecules and uses therefor
WO2001072781A2 (fr) * 2000-03-28 2001-10-04 Chiron Corporation Genes humains et produits d'expression genique xvi
EP1326985A1 (fr) * 2000-08-18 2003-07-16 MERCK PATENT GmbH Identification d'un gene d'acetyltransferase n-terminale humaine
EP1407015A2 (fr) 2000-11-22 2004-04-14 Diadexus, Inc. Compositions et methodes relatives a des genes et a des proteines specifiques du sein
US7601825B2 (en) 2001-03-05 2009-10-13 Agensys, Inc. Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
WO2002083921A2 (fr) 2001-04-10 2002-10-24 Agensys, Inc. Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
DE10118452A1 (de) * 2001-04-12 2002-10-31 Joern Bullerdiek Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse
JP2005507631A (ja) * 2001-08-16 2005-03-24 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 新規ヒトｎ末端アセチルトランスフェラーゼの同定
CA2432937A1 (fr) * 2002-03-07 2003-09-07 Bf Research Institute, Inc. Gene et proteine p18abrp, et nouveau gene/proteine (p60 trp) qui supprime la mort cellulaire et nouvelles substances qui promeuvent la mort cellulaire par le biais d'une interaction avec le gene ou la proteine p18abrp
EP1426442A1 (fr) * 2002-12-02 2004-06-09 MTM Laboratories AG Marqueurs associes au lesions colorectales
US7306910B2 (en) 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
SI3611266T1 (sl) 2005-08-23 2023-02-28 The Trustees Of The University Of Pennsylvania Modificirani nukleozidi, ki vsebujejo RNA, in postopki za njihovo uporabo
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US20160032316A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (fr) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides codant pour un recepteur de lipoproteines de faible densite
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
ES2937963T3 (es) 2015-07-21 2023-04-03 Modernatx Inc Vacunas de enfermedad infecciosa
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
EP3364950A4 (fr) 2015-10-22 2019-10-23 ModernaTX, Inc. Vaccins contre des maladies tropicales
SI3718565T1 (sl) 2015-10-22 2022-08-31 Modernatx, Inc. Cepiva za respiratorni virus
JP6950123B2 (ja) * 2016-08-04 2021-10-13 静岡県 がんの発症リスクの有無を判定する方法
JP6980780B2 (ja) 2016-10-21 2021-12-15 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
EP3551193A4 (fr) 2016-12-08 2020-08-19 Modernatx, Inc. Vaccins à acide nucléique contre des virus respiratoires
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CN112233741B (zh) * 2020-09-30 2024-03-01 吾征智能技术(北京)有限公司 一种基于聚类的文本分类系统、设备、存储介质

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BALDI, A. ET AL.: "Differential expression of the retinoblastoma gene family members pRb/p105, p107, and pRb2/p130 in lung cancer.", CLINICAL CANCER RESEARCH, vol. 2, July 1996 (1996-07-01), pages 1239 - 45, XP002099965 *
CARMECI, C. ET AL.: "Identification of a gene (GPR30) with homolgy to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer.", GENOMICS, vol. 45, no. 3, 1 November 1997 (1997-11-01), pages 607 - 17, XP002099963 *
NUCLEIC ACID RESEARCH, vol. 23, no. 19, 1995, pages 4007 - 8, XP002099962 *
RADINSKY, R. ET AL.: "Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells.", CLINICAL CANCER RESEARCH, vol. 1, January 1995 (1995-01-01), pages 19 - 31, XP002099964 *
YEATMAN, T.J. ET AL.: "Identification of genetic alterations associated with the process of human experimental colon cancer liver metastasis in the nude mouse.", CLINICAL AND EXPERIMENTAL METASTASIS, vol. 14, no. 3, May 1996 (1996-05-01), pages 246 - 252, XP002099961 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9271996B2 (en) 2011-12-16 2016-03-01 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9295689B2 (en) 2011-12-16 2016-03-29 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9221891B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. In vivo production of proteins
US9233141B2 (en) 2012-04-02 2016-01-12 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9220755B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9216205B2 (en) 2012-04-02 2015-12-22 Moderna Therapeutics, Inc. Modified polynucleotides encoding granulysin
US9301993B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides encoding apoptosis inducing factor 1
US9220792B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides encoding aquaporin-5
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9149506B2 (en) 2012-04-02 2015-10-06 Moderna Therapeutics, Inc. Modified polynucleotides encoding septin-4
US9114113B2 (en) 2012-04-02 2015-08-25 Moderna Therapeutics, Inc. Modified polynucleotides encoding citeD4
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9095552B2 (en) 2012-04-02 2015-08-04 Moderna Therapeutics, Inc. Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1
US9675668B2 (en) 2012-04-02 2017-06-13 Moderna Therapeutics, Inc. Modified polynucleotides encoding hepatitis A virus cellular receptor 2
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA

Also Published As

Publication number Publication date
JP2002500010A (ja) 2002-01-08
EP1190058A2 (fr) 2002-03-27
AU2095599A (en) 1999-07-19
WO1999033982A2 (fr) 1999-07-08

Similar Documents

Publication Publication Date Title
WO1999033982A3 (fr) Genes humains et produits d'expression genique i
WO1999038972A9 (fr) Genes humains et produits ii d'expression genique
WO1999058675A3 (fr) Genes humains et produits d'expression genique v
WO2002014500A3 (fr) Genes humains et produits d'expression genique
WO2001066753A3 (fr) Nouveaux genes humains et leurs produits d'expression
EP1005540A4 (fr) Proteines ikk-beta, acides nucleiques et procedes
WO2000040614A3 (fr) Caracterisation d'une famille de canaux calciques
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
WO1999053061A3 (fr) Acides nucleiques associes a des tumeurs et leur emploi
WO2001005825A3 (fr) Nouveaux procedes et materiaux des angiopoietines
WO1999064594A8 (fr) Genes et produits d'expression genique regules de façon differentielle lors du cancer de la prostate
WO2002044320A3 (fr) Genes humains de l'elongase, leurs utilisations et composes destines a leur modulation
WO2001032910A3 (fr) 27 proteines humaines secretees
WO2001012776A3 (fr) 18 proteines secretees humaines
WO2000077239A3 (fr) Nouveaux genes codant pour des proteines a des fins de diagnostic, de prevention, de therapie et autres
WO2000073323A3 (fr) Polynucléotides et polypeptides adam
WO2000077026A8 (fr) 49 proteines secretees humaines
WO2000018916A3 (fr) Genes humains et produits d'expression genique
WO2000063230A3 (fr) 49 proteines secretees humaines
WO2001072781A3 (fr) Genes humains et produits d'expression genique xvi
WO2001064876A3 (fr) Gene humain de la schizophrenie
WO2000061774A3 (fr) Proteines morphogeniques osseuses bmp
WO2000058339A3 (fr) 50 proteines humaines secretees
WO2001012775A3 (fr) 25 proteines secretees humaines
WO2001014415A3 (fr) Gènes egfh2 et produits géniques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 526638

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998965500

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1998965500

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998965500

Country of ref document: EP